IMMU stock forecast
Our latest prediction for Immunomedics, Inc.'s stock price was made on the Dec. 5, 2019 when the stock price was at 18.50$.
In the short term (2weeks), IMMU's stock price should underperform the market by -5.75%. During that period the price should oscillate between -9.81% and +9.11%.
In the medium term (3months), IMMU's stock price should underperform the market by -15.37%. During that period the price should oscillate between -34.49% and +18.49%.Get email alerts
About Immunomedics, Inc.
Immunomedics, Inc. is a clinical-stage biopharmaceutical company, which engages in the business of researching, developing, manufacturing and marketing biopharmaceutical products. It focuses on monoclonal antibody-based products for the targeted treatment of cancer. It operates through the United States, and Europe geographical segments. The company was founded by David M. Goldenberg in July 1982 and is headquartered in Morris Plains, NJ.
At the moment the company generates 1M USD in revenues.
On its last earning announcement, the company reported a loss of -1.14$ per share.
The book value per share is 2.14$
Three months stock forecastDec. 5, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|